News
UroGen — Q3 NDA Opens Hefty Revenue Opportunity (NASDAQ:URGN)
This is my third UroGen Pharma Therapeutics (NASDAQ:URGN) article after 03/2023's "UroGen: All Eyes On UGN-102 ("Eyes"). I concluded the…
Forget The Fed, These 3 REITs Could Thrive Regardless Of Interest Rate Changes
Co-produced by Austin Rogers I have pointed out multiple times how frustratingly mechanical the relationship has recently been between the…
Rexford Industrial: West Coast Remains Compelling Despite (And Because) Of The Drop (REXR)
This article was co-produced with Wolf Report We've written about Rexford Industrial (NYSE:REXR) a few times. The question that best…
Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold) (NASDAQ:CGC)
Canopy Growth (NASDAQ:CGC) is down 18%-19% since I last covered the company in April. Over the last three months, it…
W&T Offshore: $1 Handle Is A Good Entry Zone But Capital Outflow Risks Remain
Note: This article should be seen as a continuation of my prior coverage of this ticker. W&T Offshore investment thesis…
PepsiCo: This Dividend King Just Triggered A Strong Buy Signal (PEP)
PepsiCo, Inc. (NASDAQ:PEP) is known for its namesake cola, but it is also a snack food giant and has other…
S&P 500 (And Russell 2000) Earnings Look: A Quieter Period Between Now And Quarter End
To give a little voice to the Russell 2000’s earnings, this blog is going to start including some short commentary…
Check Point: A Buy Based On AI Growth Drivers And Earnings Strength
After reaching a peak of $166 in March, Check Point Software Technologies (NASDAQ:CHKP) lost ground as part of a broader…